Healthcare - Biotechnology - NASDAQ - US
$ 0.253
-38.3 %
$ 451 K
Market Cap
-0.02
P/E
CASH FLOW STATEMENT
-31.4 M
OPERATING CASH FLOW
-44.5 K
INVESTING CASH FLOW
0
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
NexImmune, Inc.
| Net Income | -32.3 M |
| Depreciation & Amortization | 1.02 M |
| Capital Expenditures | -48.7 K |
| Stock-Based Compensation | 3.55 B |
| Change in Working Capital | -4.88 M |
| Others | -4.59 B |
| Free Cash Flow | -31.5 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (32.3) | (62.5) | (50.9) | (29.9) | (20.5) | (12.8) |
| Depreciation & Amortization | 1.0 | 1.0 | 0.9 | 0.6 | 0.4 | 0.2 |
| Deferred Income Tax | 1 041.1 | 0 | (3.3) | 0.4 | 0 | 0 |
| Stock Based Compensation | 3 553.6 | 5.9 | 6.0 | 1.2 | 1.5 | 1.2 |
| Other Operating Activities | (4 589.9) | 0.5 | 0.9 | 1.3 | 2.48 K | 1.4 |
| Change in Working Capital | (4.9) | 3.9 | 0.7 | 89.4 K | (0.8) | 0.3 |
| Cash From Operations | (31.4) | (51.2) | (45.8) | (26.4) | (19.4) | (11.1) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | 48.7 K | (1.3) | (2.4) | (0.9) | (1.2) | (0.9) |
| Other Items | 4.23 K | 51.6 | (51.5) | 1.1 | 10.7 | (11.7) |
| Cash From Investing Activities | 44.5 K | 50.3 | (53.8) | 0.2 | 9.4 | (12.6) |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 9.0 | 22.4 | 18.4 K | 7.28 K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 33.3 K | 1.1 | (0.4) | 18.8 | 9.2 |
| Cash From Financing Activities | 0 | 5.2 | 124.9 | 22.1 | 18.8 | 9.2 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | (31.5) | 4.3 | 25.3 | (4.1) | 8.8 | (14.6) |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (31.5) | (52.4) | (48.1) | (27.3) | (20.7) | (12.1) |